CMNextTM is a multi-gene panel for patients with inherited cardiomyopathy. Mutations in several genes are associated with different cardiomyopathy types. Given the genetic and clinical overlap between these conditions, one comprehensive inherited cardiomyopathy test may be the most effective way of identifying at-risk individuals, or confirming a diagnosis. 
Quick Reference
Test Code 8887
Turnaround Time (TAT) 14-21 days
Number of Genes 55

Ordering Options

We now offer single site analysis (SSA) at no additional cost to family members

following single gene or panel testing* of the first family member (proband) within 90 days of the original Ambry report date.

Order Now

*excludes Exome and SNP Array tests

Why Is This Important?

Knowing if your patient has a hereditary cardiovascular disorder can help you determine their future cardiovascular disease risks and guide your medical management recommendations. Key benefits include:

  1. Clarify diagnosis and risk for sudden cardiac arrest
  2. Target medical management and prevention of cardiac arrest and other complications
  3. Offer family members genetic testing (for a familial mutation) and implement medical surveillance to only those that need it
  4. Reduce healthcare costs, resources, and anxiety for families

Mutation Detection Rate

~50% of patients with HCM or ARVD and about 30% of patients with non-ischemic DCM have a mutation in one of the CMNext genes (clinical sensitivity).  CMNext can detect >99.9% of described mutations in the included genes, when present (analytic sensitivity).

Test Description

CMNext includes 55 genes that cause cardiomyopathy (listed above). These genes are also included in the comprehensive cardiovascular genetics (CardioNext) panel. Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using a standardized kit and quantified. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides is carried out by a bait-capture methodology using long biotinylated oligonucleotide probes, followed by polymerase chain reaction (PCR) and NGS. Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing. This assay targets all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. Gross deletion/duplication analysis for available genes is performed using a custom pipeline based on read-depth from NGS data and/or targeted chromosomal microarray with confirmatory MLPA when applicable.

View Full Menu

Search Results

Start your search...